6-K: European Commission Approves Expanded Age Indication for Gsk's Arexvy, The First Respiratory Syncytial Virus (Rsv) Vaccine for Adults Aged 50-59 at Increased Risk
6-K: European Commission Approves Expanded Age Indication for Gsk's Arexvy, The First Respiratory Syncytial Virus (Rsv) Vaccine for Adults Aged 50-59 at Increased Risk
歐盟委員會批准擴大葛蘭素史克Arexvy的適用年齡，這是首個針對50-59歲高危成年人的呼吸道合胞病毒(RSV)疫苗
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。